公开(公告)号：JP2013049681A

公开(公告)日：2013-03-14

申请号：JP2012225875

申请日：2012-10-11

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： WAGNER ROLF ,  TUFANO MICHAEL D ,  STEWART KENT D ,  ROCKWAY TODD W ,  RANDOLPH JOHN T ,  PRATT JOHN K ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LONGENECKER KENTON L ,  LIU YAYA ,  LIU DACHUN ,  KRUEGER ALLAN C ,  KATI WARREN M ,  HUTCHINSON DOUGLAS K ,  HUANG PEGGY P ,  FLENTGE CHARLES A ,  DONNER PAMELA L ,  DEGOEY DAVID A ,  BETEBENNER DAVID A ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  SARRIS KATHY ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/513 ,  A61K31/5377 ,  A61P1/16 ,  A61P31/14 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.

Abstract translation: 待解决的问题：提供可用于治疗丙型肝炎（HCV）感染的化合物。 解决方案：在化合物中，尿嘧啶或胸腺嘧啶衍生物通过亚苯连接成稠合的2-环环系（R6），或者通过另外的两个原子连接基（L）连接到5-6元单环（R6 ）。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯基） 萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基苯乙烯基 苯基）甲磺酰胺。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：JP2013056886A

公开(公告)日：2013-03-28

申请号：JP2012221886

申请日：2012-10-04

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： FLENTGE CHARLES A ,  HUTCHINSON DOUGLAS K ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  DONNER PAMELA L ,  KATI WARREN M ,  KRUEGER ALLAN C ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  MOTTER CHRISTOPHER E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61K45/00 ,  A61P31/14 ,  A61P43/00 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

CPC classification number: C07D239/54 ,  A61K31/513 ,  A61K45/06 ,  C07D239/22 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61K2300/00

Abstract: PROBLEM TO BE SOLVED: To provide anti-infective agents and the like, used either in combination with or in lieu of an interferon agent and/or ribavirin.SOLUTION: This invention relates to: (a) compounds and salts thereof that inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 要解决的问题：提供与干扰素和/或利巴韦林组合或代替干扰素剂和/或利巴韦林使用的抗感染剂等。 本发明涉及：（a）抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：JP2013121969A

公开(公告)日：2013-06-20

申请号：JP2013008959

申请日：2013-01-22

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  SIPPY KEVIN B ,  JI JIANGUO ,  LI TAO ,  SCANIO MARC ,  SHI LEI ,  LEE CHIH-HUNG ,  BUNNELLE WILLIAM H ,  ZHANG GEOFF G Z ,  BRACKEMEYER PAUL J ,  CHEN SHUANG ,  HENRY RODGER F

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P15/08 ,  A61P17/02 ,  A61P19/02 ,  A61P21/02 ,  A61P25/04 ,  A61P25/14 ,  A61P25/18 ,  A61P25/28 ,  A61P25/34 ,  A61P29/00 ,  A61P43/00

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: PROBLEM TO BE SOLVED: To provide novel azaadamantane derivatives.SOLUTION: The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof. In the formula, Ldenotes -O- or -NR-; A denotes -Ar, -Ar-L-Aror -Ar-L-Ar; Ardenotes aryl or heteroaryl; Ardenotes aryl or monocyclic heteroaryl; Ardenotes aryl or heteroaryl; Ardenotes bicyclic heteroaryl; Ardenotes aryl or heteroaryl; Ldenotes a binding, -O -, -NR-, -CH- or -C(O)NR-; L3 denotes a binding, -O-, -NR-or -CH-; and Rdenotes hydrogen or alkyl.

Abstract translation: 待解决的问题：提供新的氮杂金刚烷衍生物。 解决方案：本发明涉及式（I）的氮杂金刚烷衍生物，特别是醚或胺取代的氮杂金刚烷衍生物及其盐和前药的化合物。 在该式中，L 1 表示-O-或-NR a - ; A表示-Ar 1 ，-Ar 2 -L 2 3 或-Ar 4 -L 3 -Ar 5 ; Ar 1 表示芳基或杂芳基; Ar 2表示芳基或单环杂芳基; Ar 3 表示芳基或杂芳基; Ar 4 表示双环杂芳基; Ar 5 表示芳基或杂芳基; L 2 表示结合，-O - ， - NR a - ，-CH 2 - 或-C（O）NR a - ; L3表示结合，-O-，-NR a - 或-CH 2 并且R a 表示氢或烷基。 版权所有（C）2013，JPO＆INPIT

公开(公告)号：WO2008058096A9

公开(公告)日：2008-06-26

申请号：PCT/US2007083687

申请日：2007-11-06

Applicant: ABBOTT LAB ,  SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  SIPPY KEVIN B ,  JI JIANGUO ,  LI TAO ,  SCANIO MARC ,  SHI LEI ,  LEE CHIH-HUNG ,  BUNNELLE WILLAIM H ,  ZHANG GEOFF G Z ,  BRACKEMEYER PAUL J ,  CHEN SHUANG ,  HENRY RODGER F

Inventor： SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  SIPPY KEVIN B ,  JI JIANGUO ,  LI TAO ,  SCANIO MARC ,  SHI LEI ,  LEE CHIH-HUNG ,  BUNNELLE WILLAIM H ,  ZHANG GEOFF G Z ,  BRACKEMEYER PAUL J ,  CHEN SHUANG ,  HENRY RODGER F

IPC: C07D451/14 ,  A61K31/395

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：WO2008058096A3

公开(公告)日：2008-08-07

申请号：PCT/US2007083687

申请日：2007-11-06

Applicant: ABBOTT LAB ,  SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  SIPPY KEVIN B ,  JI JIANGUO ,  LI TAO ,  SCANIO MARC ,  SHI LEI ,  LEE CHIH-HUNG ,  BUNNELLE WILLAIM H ,  ZHANG GEOFF G Z ,  BRACKEMEYER PAUL J ,  CHEN SHUANG ,  HENRY RODGER F

Inventor： SCHRIMPF MICHAEL R ,  NERSESIAN DIANA L ,  SIPPY KEVIN B ,  JI JIANGUO ,  LI TAO ,  SCANIO MARC ,  SHI LEI ,  LEE CHIH-HUNG ,  BUNNELLE WILLAIM H ,  ZHANG GEOFF G Z ,  BRACKEMEYER PAUL J ,  CHEN SHUANG ,  HENRY RODGER F

IPC: C07D451/14 ,  A61K31/395

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine -substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为式（I）的氮杂金刚烷衍生物的化合物，特别是醚或胺取代的氮杂金刚烷衍生物及其盐和前药，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法和 在此过程中获得的中间体。

公开(公告)号：ZA200903944B

公开(公告)日：2016-08-31

申请号：ZA200903944

申请日：2009-06-05

Applicant: ABBOTT LAB

Inventor： BRACKEMEYER PAUL J ,  SHI LEI ,  SCANIO MARC ,  SIPPY KEVIN B ,  CHEN SHUANG ,  ZHANG GEOFF G Z ,  HENRY RODGER ,  NERSESIAN DIANA L ,  BUNNELLE WILLIAM H ,  SCHRIMPF MICHAEL R ,  LEE CHIH-HUNG ,  JI JIANGUO ,  LI TAO

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

公开(公告)号：BR112013005434A2

公开(公告)日：2016-06-07

申请号：BR112013005434

申请日：2011-09-21

Applicant: ABBOTT LAB

Inventor： ZHANG GEOFF G Z ,  NAPIER JAMES J ,  BRACKEMEYER PAUL J ,  CHEN SHUANG

IPC: C07D471/08 ,  A61K31/439 ,  A61P25/00 ,  A61P25/28

Abstract: novo mono-hidrato de derivados de aza-adamantano. a invenção referes-e a mono-hidrato cristalino de citrato dihidrogenado de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-ilóxi)-1-azatriciclo[3,3,1,1^ 3,7^]decano, composições compreendendo tal compsto, e um processo para a preparação de tal composto.

公开(公告)号：AU2014280939A1

公开(公告)日：2015-01-22

申请号：AU2014280939

申请日：2014-12-24

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAUGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2,4-dioxo-3,4 dihydropyrimidin-1(2H)-yl)-2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N (4(3-t-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxy-styryl phenyl)methanesulfonamide.

公开(公告)号：CA2699989C

公开(公告)日：2014-03-25

申请号：CA2699989

申请日：2008-09-17

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L ,  RANDOLPH JOHN T ,  KRUEGER ALLAN C ,  BETEBENNER DAVID A ,  HUTCHINSON DOUGLAS K ,  LIU DACHUN ,  LIU YAYA ,  LONGENECKER KENTON L ,  MARING CLARENCE J ,  PRATT JOHN K ,  ROCKWAY TODD W ,  STEWART KENT D ,  WAGNER ROLF ,  BARNES DAVID M ,  CHEN SHUANG ,  FRANCZYK THADDEUS S II ,  GAO YI ,  HAIGHT ANTHONY R ,  HENGEVELD JOHN E ,  HENRY RODGER F ,  KOTECKI BRIAN J ,  LOU XIAOCHUN ,  ZHANG GEOFF G Z

IPC: C07D239/22 ,  A61K31/506 ,  A61K31/513 ,  A61P31/14 ,  C07D239/54 ,  C07D239/553 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)

公开(公告)号：AU2013202002A1

公开(公告)日：2013-04-18

申请号：AU2013202002

申请日：2013-03-26

Applicant: ABBOTT LAB

Inventor： KRUEGER ALLAN C ,  GAO YI ,  KOTECKI BRIAN J ,  FLENTGE CHARLES A ,  MOTTER CHRISTOPHER E ,  MARING CLARENCE J ,  LIU DACHUN ,  BETEBENNER DAVID A ,  DEGOEY DAVID A ,  BARNES DAVID M ,  HUTCHINSON DOUGLAS K ,  ZHANG GEOFF G Z ,  HENGEVELD JOHN E ,  PRATT JOHN K ,  RANDOLPH JOHN T ,  SARRIS KATHY ,  STEWART KENT D ,  LONGENECKER KENTON L ,  TUFANO MICHAEL D ,  DONNER PAMELA L ,  HUANG PEGGY P ,  HENRY RODGER F ,  WAGNER ROLF ,  CHEN SHUANG ,  FRANCZYK II THADDEUS S ,  ROCKWAY TODD W ,  KATI WARREN M ,  LOU XIAOCHUN ,  LIU YAYA ,  HAIGHT ANTHONY R

IPC: C07D239/22 ,  A61K31/513 ,  A61P31/12 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10

Abstract: URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4 dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E) N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl phenyl)methanesulfonamide.